BRPI0414480A - derivados de 2,4-di(hetero)-arilamino-pirimidina como inibidores de zap-70 e/ou syk - Google Patents

derivados de 2,4-di(hetero)-arilamino-pirimidina como inibidores de zap-70 e/ou syk

Info

Publication number: BRPI0414480A
Authority: BR; Brazil
Prior art keywords: zap; hetero; arylamino; pyrimidine derivatives; syk inhibitors
Prior art date: 2003-09-16

Application number

BRPI0414480-5A

Other languages

English (en)

Portuguese (pt)

Inventor

Rolf Baenteli

Marie Claude Bernhard

Peter Buehlmayer

Nigel Graham Cooke

Rudolf Duthaler

Klaus Hinterding

Gebhard Thoma

Maurice Van Eis

Anette Von Matt

Louis Walliser

Gerhard Zenke

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-16

Filing date

2004-09-15

Publication date

2006-11-14

2004-09-15 Application filed by Novartis Ag filed Critical Novartis Ag

2006-11-14 Publication of BRPI0414480A publication Critical patent/BRPI0414480A/pt

Links

239000003112 inhibitor Substances 0.000 title abstract 2
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title abstract 2
101100268066 Mus musculus Zap70 gene Proteins 0.000 title 1
-1 arylamino pyrimidine derivatives Chemical class 0.000 title 1
125000005842 heteroatom Chemical group 0.000 title 1
102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 abstract 1
108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 abstract 1
150000003230 pyrimidines Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)

BRPI0414480-5A 2003-09-16 2004-09-15 derivados de 2,4-di(hetero)-arilamino-pirimidina como inibidores de zap-70 e/ou syk BRPI0414480A (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0321710.6A GB0321710D0 (en)	2003-09-16	2003-09-16	Organic compounds
GBGB0414440.8A GB0414440D0 (en)	2003-09-16	2004-06-28	Organic compounds
PCT/EP2004/010348 WO2005026158A1 (fr)	2003-09-16	2004-09-15	Derives de 2,4-di(hetero)-arylamino-pyrimidine comme inhibiteurs des kinases zap-70 et/ou syk

Publications (1)

Publication Number	Publication Date
BRPI0414480A true BRPI0414480A (pt)	2006-11-14

Family

ID=29227205

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0414480-5A BRPI0414480A (pt)	2003-09-16	2004-09-15	derivados de 2,4-di(hetero)-arilamino-pirimidina como inibidores de zap-70 e/ou syk

Country Status (28)

Country	Link
US (2)	US7671063B2 (fr)
EP (2)	EP2266977B1 (fr)
JP (1)	JP4504375B2 (fr)
KR (1)	KR100813384B1 (fr)
CN (2)	CN102260248A (fr)
AR (1)	AR045747A1 (fr)
AT (1)	ATE498623T1 (fr)
AU (1)	AU2004272283B9 (fr)
BR (1)	BRPI0414480A (fr)
CA (1)	CA2538909A1 (fr)
DE (1)	DE602004031436D1 (fr)
EC (1)	ECSP066424A (fr)
ES (2)	ES2361412T3 (fr)
GB (2)	GB0321710D0 (fr)
IL (1)	IL174217A0 (fr)
IS (1)	IS8402A (fr)
MA (1)	MA28076A1 (fr)
MX (1)	MXPA06002966A (fr)
NO (1)	NO20061656L (fr)
PE (1)	PE20050429A1 (fr)
PL (1)	PL1664035T3 (fr)
PT (1)	PT1664035E (fr)
RU (1)	RU2403251C2 (fr)
SG (1)	SG132676A1 (fr)
TN (1)	TNSN06083A1 (fr)
TW (1)	TW200521118A (fr)
WO (1)	WO2005026158A1 (fr)
ZA (1)	ZA200601963B (fr)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) *	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
IL166241A0 (en)	2002-07-29	2006-01-15	Rigel Pharmaceuticals Inc	Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
GB0305929D0 (en) *	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
ES2421139T3 (es)	2003-07-30	2013-08-29	Rigel Pharmaceuticals, Inc.	Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
ATE542801T1 (de) *	2003-08-15	2012-02-15	Novartis Ag	Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
GB0321710D0 (en) *	2003-09-16	2003-10-15	Novartis Ag	Organic compounds
US7449458B2 (en)	2005-01-19	2008-11-11	Rigel Pharmaceuticals, Inc.	Prodrugs of 2,4-pyrimidinediamine compounds and their uses
JP5186219B2 (ja) *	2005-01-25	2013-04-17	エピックスデラウェア，インコーポレイテッド	置換アリールアミン化合物および５−ｈｔ６調節因子としてのその使用
WO2006129100A1 (fr) *	2005-06-03	2006-12-07	Glaxo Group Limited	Nouveaux composes
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (fr)	2005-06-08	2006-12-14	Rigel Pharmaceuticals, Inc.	Compositions et procedes d'inhibition de la voie jak
GB0517329D0 (en) *	2005-08-25	2005-10-05	Merck Sharp & Dohme	Stimulation of neurogenesis
US8604042B2 (en)	2005-11-01	2013-12-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en)	2005-11-01	2012-03-13	Targegen, Inc.	Use of bi-aryl meta-pyrimidine inhibitors of kinases
WO2007053452A1 (fr)	2005-11-01	2007-05-10	Targegen, Inc.	Inhibiteurs de kinase de type biaryl-méta-pyrimidine
JP2009520038A (ja) *	2005-12-19	2009-05-21	ジェネンテック・インコーポレーテッド	ピリミジンキナーゼインヒビター
WO2007085540A1 (fr) *	2006-01-27	2007-08-02	Glaxo Group Limited	Derives 1h-indaz0l-4-yl-2,4-pyrimidinediamine
EA200870217A1 (ru) *	2006-01-30	2009-02-27	Экселиксис, Инк.	4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
KR101411695B1 (ko)	2006-02-17	2014-07-03	리겔 파마슈티칼스, 인크.	자가면역 질환의 치료 또는 예방을 위한 2,4-피리미딘디아민 화합물
WO2007098507A2 (fr)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions et méthodes destinées à l'inhibition de la voie jak
US8168383B2 (en)	2006-04-14	2012-05-01	Cell Signaling Technology, Inc.	Gene defects and mutant ALK kinase in human solid tumors
PL2450437T3 (pl)	2006-04-14	2017-12-29	Cell Signaling Technology Inc	Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
MX2009004426A (es)	2006-10-23	2009-08-12	Cephalon Inc	Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
EA019941B1 (ru)	2006-12-08	2014-07-30	АйАрЭм ЭлЭлСи	Соединения и композиции в качестве ингибиторов протеинкиназы
CA2670645A1 (fr) *	2006-12-19	2008-07-03	Genentech, Inc.	Inhibiteurs de pyrimidine kinase
PE20081636A1 (es)	2007-01-26	2009-01-10	Smithkline Beecham Corp	Inhibidores de antranilamida para aurora quinasa
TW200840581A (en) *	2007-02-28	2008-10-16	Astrazeneca Ab	Novel pyrimidine derivatives
MX2009011199A (es)	2007-04-16	2010-03-17	Hutchison Medipharma Entpr Ltd	Derivados de pirimidina.
TWI389893B (zh) *	2007-07-06	2013-03-21	Astellas Pharma Inc	二（芳胺基）芳基化合物
BRPI0815979A2 (pt) *	2007-08-28	2017-06-13	Irm Llc	compostos e composições com inibidores de quinase, bem como uso dos mesmos
RU2490015C2 (ru)	2008-02-22	2013-08-20	Райджел Фармасьютикалз, Инк.	Применение 2,4-пиримидиндиаминов для лечения атеросклероза
US20110098288A1 (en) *	2008-03-11	2011-04-28	Jeremy Major	Sulfonamides as zap-70 inhibitors
WO2009127642A2 (fr) *	2008-04-15	2009-10-22	Cellzome Limited	Utilisation d’inhibiteurs de lrrk2 pour maladies neurodégénératives
US8138339B2 (en)	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
US8063058B2 (en)	2008-04-16	2011-11-22	Portola Pharmaceuticals, Inc.	Inhibitors of syk and JAK protein kinases
US7829574B2 (en)	2008-05-09	2010-11-09	Hutchison Medipharma Enterprises Limited	Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
JP2011523646A (ja)	2008-05-21	2011-08-18	アリアド・ファーマシューティカルズ・インコーポレイテッド	キナーゼ阻害剤としてのリン誘導体
US8445505B2 (en)	2008-06-25	2013-05-21	Irm Llc	Pyrimidine derivatives as kinase inhibitors
WO2009158431A2 (fr) *	2008-06-25	2009-12-30	Irm Llc	Composés et compositions en tant qu’inhibiteurs de kinase
PE20100087A1 (es)	2008-06-25	2010-02-08	Irm Llc	Compuestos y composiciones como inhibidores de cinasa
AU2009262068C1 (en) *	2008-06-27	2015-07-02	Celgene Car Llc	Heteroaryl compounds and uses thereof
US11351168B1 (en)	2008-06-27	2022-06-07	Celgene Car Llc	2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) *	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
US8426430B2 (en)	2008-06-30	2013-04-23	Hutchison Medipharma Enterprises Limited	Quinazoline derivatives
TW201008933A (en)	2008-08-29	2010-03-01	Hutchison Medipharma Entpr Ltd	Pyrimidine compounds
JP2012501654A (ja) *	2008-09-05	2012-01-26	アビラセラピューティクス，インコーポレイテッド	不可逆的インヒビターの設計のためのアルゴリズム
KR101705158B1 (ko)	2009-05-05	2017-02-09	다나-파버 캔서 인스티튜트 인크.	Ｅｇｆｒ 억제제 및 질환 치료방법
EP2440534A2 (fr) *	2009-06-10	2012-04-18	Cellzome Limited	Dérivés de pyrimidine en tant qu'inhibiteurs zap-70
WO2010146132A1 (fr) *	2009-06-18	2010-12-23	Cellzome Limited	Sulfonamides et sulfamides servant d'inhibiteurs de la zap-70
CN102713618B (zh)	2009-09-16	2015-07-15	新基阿维罗米克斯研究公司	蛋白激酶复合物和抑制剂
WO2011082285A1 (fr)	2009-12-30	2011-07-07	Avila Therapeutics, Inc.	Modification covalente de protéine, dirigée sur un ligand
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
US20120101108A1 (en)	2010-08-06	2012-04-26	Cell Signaling Technology, Inc.	Anaplastic Lymphoma Kinase In Kidney Cancer
PH12013500246A1 (en)	2010-08-10	2019-10-11	Celgene Avilomics Res Inc	Besylate salt of a btk inhibitor
JP5956999B2 (ja)	2010-11-01	2016-07-27	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	ヘテロアリール化合物およびその使用
BR112013010564B1 (pt)	2010-11-01	2021-09-21	Celgene Car Llc	Compostos heterocíclicos e composições compreendendo os mesmos
AU2010363329A1 (en)	2010-11-07	2013-05-09	Targegen, Inc.	Compositions and methods for treating myelofibrosis
EP2637502B1 (fr)	2010-11-10	2018-01-10	Celgene CAR LLC	Inhibiteurs d'egfr sélectifs d'un mutant et leurs utilisations
EP2489663A1 (fr)	2011-02-16	2012-08-22	Almirall, S.A.	Composés en tant qu'inhibiteurs de la syk kinase
JP5931933B2 (ja)	2011-02-25	2016-06-08	武田薬品工業株式会社	Ｎ−置換オキサジノプテリジンおよびオキサジノプテリジノン
US9249124B2 (en)	2011-03-30	2016-02-02	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Aurora kinase inhibitors and methods of making and using thereof
AU2012250517B2 (en)	2011-05-04	2016-05-19	Takeda Pharmaceutical Company Limited	Compounds for inhibiting cell proliferation in EGFR-driven cancers
CA2834062A1 (fr)	2011-05-10	2012-11-15	Merck Sharp & Dohme Corp.	Pyridylaminopyridines en tant qu'inhibiteurs de syk
WO2012154518A1 (fr)	2011-05-10	2012-11-15	Merck Sharp & Dohme Corp.	Bipyridylaminopyridines en tant qu'inhibiteurs de syk
AU2012253885A1 (en)	2011-05-10	2013-10-31	Merck Sharp & Dohme Corp.	Aminopyrimidines as Syk inhibitors
US8987456B2 (en)	2011-10-05	2015-03-24	Merck Sharp & Dohme Corp.	3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
WO2013052391A1 (fr)	2011-10-05	2013-04-11	Merck Sharp & Dohme Corp.	Inhibiteurs de tyrosine kinase de la rate (syk) contenant un phényl carboxamide
EP2763976B1 (fr)	2011-10-05	2016-05-18	Merck Sharp & Dohme Corp.	Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 2-pyridyl carboxamide
JP2014532658A (ja)	2011-10-28	2014-12-08	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	ブルトン型チロシンキナーゼ疾患または障害を治療する方法
EP2782579B1 (fr)	2011-11-23	2019-01-02	Portola Pharmaceuticals, Inc.	Inhibiteurs de de la pyrazine kinase
US9073944B2 (en) *	2012-02-21	2015-07-07	Merck Patent Gmbh	Cyclic diaminopyrimidine derivatives
JP6317320B2 (ja)	2012-03-15	2018-04-25	セルジーンシーエーアールエルエルシー	上皮成長因子受容体キナーゼ阻害剤の塩
ES2880109T3 (es)	2012-03-15	2021-11-23	Celgene Car Llc	Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
AR090650A1 (es)	2012-04-12	2014-11-26	Alcon Res Ltd	Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
JP6469567B2 (ja)	2012-05-05	2019-02-13	アリアド・ファーマシューティカルズ・インコーポレイテッド	Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2013192125A1 (fr)	2012-06-20	2013-12-27	Merck Sharp & Dohme Corp.	Dérivés de pyrazolyle en tant qu'inhibiteurs de syk
EP2863913B1 (fr)	2012-06-20	2018-09-12	Merck Sharp & Dohme Corp.	Analogues d'imidazolyle en tant qu'inhibiteurs de syk
US9376418B2 (en)	2012-06-22	2016-06-28	Merck Sharp & Dohme Corp.	Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
WO2013192088A1 (fr)	2012-06-22	2013-12-27	Merck Sharp & Dohme Corp.	Inhibiteurs de tyrosine kinase splénique (syk) diazines et triazines substituées
EP2884982B1 (fr)	2012-08-20	2017-09-20	Merck Sharp & Dohme Corp.	Inhibiteurs de la phényle tyrosine kinase de la rate (syk) substitués
WO2014048065A1 (fr)	2012-09-28	2014-04-03	Merck Sharp & Dohme Corp.	Dérivés triazolyle en tant qu'inhibiteurs de la syk
RU2702908C2 (ru)	2012-11-01	2019-10-14	Инфинити Фармасьютикалз, Инк.	Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
EP2931281B1 (fr)	2012-12-12	2018-01-17	Merck Sharp & Dohme Corp.	Inhibiteurs de tyrosine kinase splénique contenant une aminopyridine
EP2934525B1 (fr)	2012-12-21	2019-05-08	Merck Sharp & Dohme Corp.	Aminopyridines substituées par thiazole en tant qu'inhibiteurs de la tyrosine kinase de la rate
US9126950B2 (en)	2012-12-21	2015-09-08	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
CN105188371A (zh)	2013-02-08	2015-12-23	西建阿维拉米斯研究公司	Erk抑制剂及其用途
WO2014128235A1 (fr)	2013-02-22	2014-08-28	F. Hoffmann-La Roche Ag	Méthodes de traitement du cancer et de prévention de résistance aux médicaments
NZ629037A (en)	2013-03-15	2017-04-28	Infinity Pharmaceuticals Inc	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US10150742B2 (en)	2013-03-15	2018-12-11	President And Fellows Of Harvard College	Substituted heterocyclic compounds for treating or preventing viral infections
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
EP2988744A4 (fr)	2013-04-26	2016-11-02	Merck Sharp & Dohme	Composés aminohétéroaryle à substitution thiazole inhibiteurs de tyrosine kinase splénique
WO2014176216A1 (fr)	2013-04-26	2014-10-30	Merck Sharp & Dohme Corp.	Aminopyrimidines substituées par thiazole utilisées en tant qu'inhibiteurs de tyrosine kinase splénique
KR20160013204A (ko)	2013-05-30	2016-02-03	인피니티 파마슈티칼스, 인코포레이티드	Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
US9492471B2 (en)	2013-08-27	2016-11-15	Celgene Avilomics Research, Inc.	Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
EP3964507A1 (fr)	2013-10-04	2022-03-09	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
WO2015051241A1 (fr)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
ES2968371T3 (es)	2013-10-10	2024-05-09	Eastern Virginia Medical School	Derivados de 4-((2-hidroxi-3-metoxibencil)amino) bencenosulfonamida como inhibidores de la 12-lipoxigenasa
US20160244452A1 (en)	2013-10-21	2016-08-25	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3083559B1 (fr)	2013-12-20	2021-03-10	Merck Sharp & Dohme Corp.	Composés aminohétéroaryles à substitution thiazole utilisés comme inhibiteurs de la tyrosine kinase splénique
WO2015094997A1 (fr)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Composés aminohétéroaryle à substitution thiazole utilisés comme inhibiteurs de la tyrosine kinase splénique
US9415049B2 (en)	2013-12-20	2016-08-16	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
US9670196B2 (en)	2013-12-20	2017-06-06	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
US9371321B2 (en)	2014-01-09	2016-06-21	Astrazeneca Ab	Azaindole derivatives
WO2015138273A1 (fr)	2014-03-13	2015-09-17	Merck Sharp & Dohme Corp.	Composés 2-pyrazine carboxamide utiles comme inhibiteurs de la tyrosine kinase splénique
CN106456628A (zh)	2014-03-19	2017-02-22	无限药品股份有限公司	用于治疗PI3K‑γ介导的障碍的杂环化合物
US20150320754A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2016025561A1 (fr)	2014-08-13	2016-02-18	Celgene Avilomics Research, Inc.	Formes et compositions d'un inhibiteur d'erk
WO2016054491A1 (fr)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
CN106146525B (zh) *	2015-04-10	2018-11-02	山东轩竹医药科技有限公司	三并环类间变性淋巴瘤激酶抑制剂
CN114230571B (zh)	2015-09-14	2025-07-08	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
CN105664178B (zh) *	2015-09-24	2019-08-20	洪健	Syk作为肝纤维化/硬化治疗靶点的应用
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3474856B1 (fr)	2016-06-24	2022-09-14	Infinity Pharmaceuticals, Inc.	Therapies combinées
AR111760A1 (es)	2017-05-19	2019-08-14	Novartis Ag	Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
WO2019090205A1 (fr)	2017-11-06	2019-05-09	Snap Bio, Inc.	Compositions d'inhibiteur de kinase pim, procédés et utilisations de celles-ci
WO2019154091A1 (fr) *	2018-02-07	2019-08-15	深圳市塔吉瑞生物医药有限公司	Composé de diaminopyrimidine substituée
KR102063155B1 (ko)	2018-04-11	2020-01-08	한국과학기술연구원	우수한 카이네이즈 저해 활성을 보이는 다양한 치환기를 갖는 피리미딘 유도체
CA3129665A1 (fr)	2019-03-21	2020-09-24	Onxeo	Molecule dbait associee a un inhibiteur de kinase pour le traitement du cancer
CN114072394A (zh)	2019-04-25	2022-02-18	拜耳股份公司	用于治疗癌症的酰基磺酰胺
CN112469713B (zh) *	2019-06-21	2023-09-01	江苏豪森药业集团有限公司	芳基磷氧化物类衍生物抑制剂、其制备方法和应用
AU2020300619A1 (en)	2019-07-03	2022-01-27	Sumitomo Pharma Oncology, Inc.	Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
KR20220098759A (ko)	2019-11-08	2022-07-12	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	키나제 억제제에 대해 내성을 획득한 암의 치료 방법
US20230026840A1 (en) *	2019-11-21	2023-01-26	Tyk Medicines, Inc.	Compound used as egfr kinase inhibitor and use thereof
CN111423419B (zh) *	2020-01-17	2021-12-17	温州医科大学	一种小分子化合物cyy-260及其在制备抗肿瘤药物中的应用
WO2021148581A1 (fr)	2020-01-22	2021-07-29	Onxeo	Nouvelle molécule dbait et son utilisation
JP2023513016A (ja) *	2020-01-30	2023-03-30	スミトモファーマオンコロジー，インコーポレイテッド	Ｎｅｋ２阻害剤としてのアミノピリミジニルアミノベンゾニトリル誘導体
CN111484484B (zh) *	2020-04-13	2021-11-23	沈阳药科大学	含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用
US12679822B2 (en)	2020-06-08	2026-07-14	Hongyun Biotech Co., Ltd.	Alkenyl pyrimidine compound, preparation method therefor, and application thereof
CN118955502A (zh) *	2020-07-23	2024-11-15	上海赛岚生物科技有限公司	一类具有激酶抑制活性的化合物
EP4185279A4 (fr)	2020-07-24	2024-05-01	Secura Bio, Inc.	Traitement de cancers à l'aide de modulateurs d'isoformes de la pi3-kinase
CN114644654A (zh) *	2020-12-18	2022-06-21	上海翰森生物医药科技有限公司	芳基磷氧化衍生物、酸式盐或其晶型及其制备方法和应用
TW202321228A (zh) *	2021-08-06	2023-06-01	大陸商南京紅云生物科技有限公司	苯並二噁烷類化合物、其製備方法與應用
CN117736198A (zh) *	2022-09-21	2024-03-22	科辉智药生物科技(深圳)有限公司	大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
GB9619284D0 (en) *	1996-09-16	1996-10-30	Celltech Therapeutics Ltd	Chemical compounds
GB9622363D0 (en) *	1996-10-28	1997-01-08	Celltech Therapeutics Ltd	Chemical compounds
GB9705361D0 (en)	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
GB9721069D0 (en)	1997-10-03	1997-12-03	Pharmacia & Upjohn Spa	Polymeric derivatives of camptothecin
AU5438299A (en) *	1998-08-29	2000-03-21	Astrazeneca Ab	Pyrimidine compounds
GB9828511D0 (en) *	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
MXPA02003436A (es)	1999-10-07	2002-08-20	Amgen Inc	Inhibidores de triazina cinasa.
KR20030024659A (ko) *	2000-02-17	2003-03-26	암겐 인코포레이티드	키나제 억제제
GB0004887D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0019632D0 (en)	2000-08-09	2000-09-27	Novartis Ag	Organic compounds
US20020132823A1 (en)	2001-01-17	2002-09-19	Jiahuai Han	Assay method
US6939874B2 (en) *	2001-08-22	2005-09-06	Amgen Inc.	Substituted pyrimidinyl derivatives and methods of use
WO2003030909A1 (fr) *	2001-09-25	2003-04-17	Bayer Pharmaceuticals Corporation	2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
TWI329105B (en) *	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) *	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
UA80767C2 (en) *	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
ES2325440T3 (es) *	2003-02-20	2009-09-04	Smithkline Beecham Corporation	Compuestos de pirimidina.
GB0305929D0 (en) *	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
GB0321710D0 (en) *	2003-09-16	2003-10-15	Novartis Ag	Organic compounds
AU2004272288B2 (en) *	2003-09-18	2008-11-13	Novartis Ag	2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
ATE540035T1 (de)	2004-11-24	2012-01-15	Rigel Pharmaceuticals Inc	Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen

2003
- 2003-09-16 GB GBGB0321710.6A patent/GB0321710D0/en not_active Ceased
2004
- 2004-06-28 GB GBGB0414440.8A patent/GB0414440D0/en not_active Ceased
- 2004-09-14 PE PE2004000887A patent/PE20050429A1/es not_active Application Discontinuation
- 2004-09-14 AR ARP040103281A patent/AR045747A1/es not_active Application Discontinuation
- 2004-09-15 CN CN2011101453147A patent/CN102260248A/zh active Pending
- 2004-09-15 AU AU2004272283A patent/AU2004272283B9/en not_active Ceased
- 2004-09-15 AT AT04786952T patent/ATE498623T1/de active
- 2004-09-15 ES ES04786952T patent/ES2361412T3/es not_active Expired - Lifetime
- 2004-09-15 ES ES10178291.0T patent/ES2487534T3/es not_active Expired - Lifetime
- 2004-09-15 BR BRPI0414480-5A patent/BRPI0414480A/pt not_active IP Right Cessation
- 2004-09-15 SG SG200703520-7A patent/SG132676A1/en unknown
- 2004-09-15 KR KR1020067005207A patent/KR100813384B1/ko not_active Expired - Fee Related
- 2004-09-15 WO PCT/EP2004/010348 patent/WO2005026158A1/fr not_active Ceased
- 2004-09-15 EP EP10178291.0A patent/EP2266977B1/fr not_active Expired - Lifetime
- 2004-09-15 TW TW093127876A patent/TW200521118A/zh unknown
- 2004-09-15 PT PT04786952T patent/PT1664035E/pt unknown
- 2004-09-15 MX MXPA06002966A patent/MXPA06002966A/es active IP Right Grant
- 2004-09-15 JP JP2006526583A patent/JP4504375B2/ja not_active Expired - Fee Related
- 2004-09-15 PL PL04786952T patent/PL1664035T3/pl unknown
- 2004-09-15 RU RU2006112593/04A patent/RU2403251C2/ru not_active IP Right Cessation
- 2004-09-15 DE DE602004031436T patent/DE602004031436D1/de not_active Expired - Lifetime
- 2004-09-15 CN CN2004800336712A patent/CN1882578B/zh not_active Expired - Fee Related
- 2004-09-15 EP EP04786952A patent/EP1664035B1/fr not_active Expired - Lifetime
- 2004-09-15 CA CA002538909A patent/CA2538909A1/fr not_active Abandoned
2006
- 2006-03-08 ZA ZA200601963A patent/ZA200601963B/en unknown
- 2006-03-09 IL IL174217A patent/IL174217A0/en unknown
- 2006-03-15 TN TNP2006000083A patent/TNSN06083A1/en unknown
- 2006-03-16 US US11/377,716 patent/US7671063B2/en not_active Expired - Fee Related
- 2006-03-16 EC EC2006006424A patent/ECSP066424A/es unknown
- 2006-03-27 MA MA28893A patent/MA28076A1/fr unknown
- 2006-04-07 IS IS8402A patent/IS8402A/is unknown
- 2006-04-11 NO NO20061656A patent/NO20061656L/no not_active Application Discontinuation
2010
- 2010-01-13 US US12/686,863 patent/US8283356B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PT1664035E (pt)	2011-05-03
GB0414440D0 (en)	2004-07-28
EP1664035A1 (fr)	2006-06-07
US20100152182A1 (en)	2010-06-17
ES2361412T3 (es)	2011-06-16
JP4504375B2 (ja)	2010-07-14
AU2004272283B2 (en)	2008-10-02
TNSN06083A1 (en)	2007-10-03
KR100813384B1 (ko)	2008-03-12
CN1882578B (zh)	2011-07-20
DE602004031436D1 (de)	2011-03-31
MXPA06002966A (es)	2006-05-31
US7671063B2 (en)	2010-03-02
MA28076A1 (fr)	2006-08-01
ATE498623T1 (de)	2011-03-15
ES2487534T3 (es)	2014-08-21
CN1882578A (zh)	2006-12-20
AR045747A1 (es)	2005-11-09
NO20061656L (no)	2006-06-16
TW200521118A (en)	2005-07-01
ECSP066424A (es)	2006-09-18
CA2538909A1 (fr)	2005-03-24
RU2403251C2 (ru)	2010-11-10
AU2004272283A1 (en)	2005-03-24
EP1664035B1 (fr)	2011-02-16
EP2266977A1 (fr)	2010-12-29
ZA200601963B (en)	2007-05-30
EP2266977B1 (fr)	2014-05-14
IS8402A (is)	2006-04-07
KR20060056388A (ko)	2006-05-24
JP2007505856A (ja)	2007-03-15
US20060247262A1 (en)	2006-11-02
GB0321710D0 (en)	2003-10-15
AU2004272283B9 (en)	2008-10-23
PE20050429A1 (es)	2005-07-14
PL1664035T3 (pl)	2011-07-29
WO2005026158A1 (fr)	2005-03-24
IL174217A0 (en)	2006-08-01
US8283356B2 (en)	2012-10-09
CN102260248A (zh)	2011-11-30
SG132676A1 (en)	2007-06-28
RU2006112593A (ru)	2007-11-10

Legal Events

Date	Code	Title	Description
2011-03-22	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2011-04-26	B15K	Others concerning applications: alteration of classification	Free format text: PARA: INT. CL. C07D 405/12, 239/48, 405/14, 413/14, 417/14, 403/12; A61K 31/506; A61P 35/00 Ipc: C07D 405/12 (2011.01), C07D 239/48 (2011.01), C07D
2014-04-22	B08L	Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]	Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A E 9A ANUIDADES.
2020-11-10	B08I	Publication cancelled [chapter 8.9 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.
2020-11-17	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 8A, 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.
2021-03-09	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0408347A (pt)	2006-03-21	derivados de pirimidina
BRPI0412347A (pt)	2006-09-05	2-aminofenil-4-fenilpiridinas como inibidores de quinase
BR0208338A (pt)	2004-03-09	Derivados de piridina
BRPI0512938A (pt)	2008-04-15	derivados da quinazolinediona como inibidores parp
BR0308461A (pt)	2005-01-18	Derivados de pirimidina
BRPI0512790A (pt)	2008-04-08	derivados de 2-alquil quinazolinona substituìdos como inibidores de parp
CR9602A (es)	2008-03-05	Nuevos derivados de 2,4-dianilinpirimidinas, su preparacion, como medicamentos, composiciones farmaceuticas y particularmente como inhibidores de ikk
BRPI0411721A (pt)	2006-05-23	derivados de tiazolilpiperidina como inibidores de mtp
BRPI0511621A (pt)	2008-01-02	compostos orgánicos
ECSP066424A (es)	2006-09-18	Derivados de 2,4-di-(hetero)-aril-amino-pirimidina como inhibidores de zap-70 y/o syk
BR0207278A (pt)	2004-02-10	Derivados de ftalazinona-piperidina como inibidores de pde4
BR0309556A (pt)	2005-02-09	Inibidores de metaloproteinase pirimidina-2,4,6-triona
BRPI0409164A (pt)	2006-04-11	pirazóis substituìdos
BRPI0512902A (pt)	2008-04-15	derivados de ftalazina como inibidores de parp
BR0316350A (pt)	2005-09-27	Diaminotriazóis úteis como inibidores de proteìna cinases
BRPI0814065B8 (pt)	2021-05-25	derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
BRPI0513901A (pt)	2008-05-20	derivados de uréia cìclicos substituìdos, preparação dos mesmos e uso farmacêutico dos mesmos como inibidores de cinase
BRPI0513863A (pt)	2008-05-20	derivados de uréia cìclica substituìda por heterociclo, preparação dos mesmos e uso farmacêutico dos mesmos como inibidores de cinase
BR0312129A (pt)	2005-03-29	Derivados de espiroindolinapiperidina
BRPI0515594A (pt)	2008-07-29	inibidores da interação entre mdm2 e p53
BRPI0510273A (pt)	2007-10-30	derivados de tetraazabenzo[e]azuleno e análogos destes
BR0013081A (pt)	2002-04-23	Pirimidino-2,4,6-trionas inibidoras de metaloproteinases
BRPI0606379A2 (pt)	2009-06-23	triazolftalazinas
BRPI0414948A (pt)	2006-11-07	derivados de pirazolo-e-imidazo pirimidina
BRPI0514731A (pt)	2008-06-24	derivados de pirimidina